Importantly, the effects of empagliflozin were comparable to those of semaglutide, which has demonstrated histological improvements in NASH in recent clinical trials [40,44], indicating that empagliflozin may represent an alternative therapeutic candidate alongside GLP-1 receptor agonists. Here, GLP1R is linked to metabolic dysfunction-associated steatohepatitis.